- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02983682
Lidocaine Infusions for Chronic Pain in Children
January 17, 2024 updated by: Lisa Isaac, The Hospital for Sick Children
A Pilot Study of the Effectiveness of Lidocaine Infusions for the Management of Chronic Pain in Children
This is a study to evaluate the efficacy and safety of lidocaine in the management of chronic pain in children.
All participants will receive lidocaine infusion and severity of pain and degree of chronic-pain related disability will be assessed before and up to 4 weeks after infusion.
Adverse events will be recorded.
Study Overview
Detailed Description
Reports have shown that intravenous lidocaine infusions have been effective in relieving chronic pain that has been resistant to other therapies, with minimal side effects.
The investigators would like to determine whether severity of pain and degree of chronic-pain related disability could be reduced with lidocaine infusion in children and to understand whether the dose of lidocaine correlates with blood levels in the same manner as it does in adults.
The investigators will recruit 24 patients aged 8-18 with chronic pain that has not been relieved by standard therapies.
Each patient will receive a lidocaine infusion over 2 hours.
Blood will be drawn for lidocaine concentration before the beginning of the infusion, immediately after and 0.5, 2 and 4 hours after.
Severity of pain and degree of disability will be recorded using a questionnaire measuring pain scores, sleep disruption, social disruption, physical abilities and school attendance before the infusion, weekly for 2 weeks and then 4 weeks after.
This study will help the investigators better understand the effectiveness and safety of intravenous lidocaine for chronic pain in children.
Study Type
Interventional
Enrollment (Actual)
19
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lisa Isaac, MD
- Phone Number: 416-813-6410
- Email: lisa.isaac@sickkids.ca
Study Contact Backup
- Name: Carolyne Pehora, RN
- Phone Number: 202406 416-813-7654
- Email: carolyne.pehora@sickkids.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- The Hospital for Sick Children
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosed with a chronic pain condition (> 3 months) other conventional medical therapies (anticonvulsants, tricyclics etc), have not been effective.
- American Society of Anesthesiologists class 1 or 2
- Age 8-18 years
- Ability to understand and use the numeric rating scale to rate their pain and to understand and answer other questionnaires
- Negative pregnancy test in participants of child-bearing potential (Females 12 years of age and older, or menarchal if under 12)
Exclusion Criteria:
- History of seizures
- Known liver or renal disease
- Patient taking strong CYP1A2 inducers or inhibitors (fluvoxamine, phenytoin, cimetidine, amiodarone) or beta blockers (propranolol, metoprolol, nadolol)
- Allergy or sensitivity to lidocaine or other local anesthetic
- Cardiac conduction anomalies (eg. Heart block, Wolff-Parkinson-White)
- Serum electrolytes (potassium, sodium, magnesium or calcium) outside of reference ranges
- Pregnancy
Withdrawal Criteria
- Patient or parent/guardian request
- Refusal to have intravenous access and serum levels drawn
- Inability to complete pain scores on the questionnaires (paper or electronic) at the first infusion and weekly for 2 weeks and at one month following infusion
- Baseline free carnitine concentration < 26 micromoles/L or total carnitine < 32 micromoles/L (reference values from SickKids Department of Pediatric Laboratory Medicine "Guide to Laboratory Services")
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lidocaine Infusion
All participants will receive intravenous lidocaine infusion of 42 mcg/kg/minute over 2 hours, for a total of 5 mg/kg.
No bolus dose will be given.
|
Patients will receive lidocaine infusion of 42 micrograms/kg/minute over tow hours for a total of 5 mg/kg.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Score
Time Frame: Change from baseline pain score (7 days prior to infusion) at 14 days after completion of infusion
|
Pain scores will be measured using the Numeric Rating Scale
|
Change from baseline pain score (7 days prior to infusion) at 14 days after completion of infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Analgesic Requirement
Time Frame: Up to seven days prior to lidocaine infusion.
|
Participants will record all analgesics used in a pain diary provided by the investigators.
|
Up to seven days prior to lidocaine infusion.
|
Analgesic Requirement
Time Frame: Up to one month after lidocaine infusion
|
Participants will record all analgesics used in a pain diary provided by the investigators.
|
Up to one month after lidocaine infusion
|
Adverse Events
Time Frame: intraoperative
|
Participants will be monitored for adverse events including cardiac arrhythmias, hypotension, hypertension, tachycardia, metallic taste, tinnitus, lightheadedness, nausea, vomiting and headache
|
intraoperative
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep
Time Frame: Day of the infusion, one week, two weeks and four weeks following the infusion.
|
The Adolescent Sleep Wake Scale will be used to assess quantity and quality of sleep.
|
Day of the infusion, one week, two weeks and four weeks following the infusion.
|
Pain Interference
Time Frame: Day of the infusion, one week, two weeks and four weeks following infusion.
|
The Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Scale will be used to measure how pain interferes with the participants activities of daily living
|
Day of the infusion, one week, two weeks and four weeks following infusion.
|
School Attendance
Time Frame: Week prior to the infusion and at two and four weeks following the infusion.
|
Participants will record the number of hours of school attendance where relevant (e.g.
no school holidays, no medical appointments).
|
Week prior to the infusion and at two and four weeks following the infusion.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lisa Isaac, MD, The Hospital for Sick Children
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2017
Primary Completion (Actual)
December 1, 2023
Study Completion (Actual)
December 1, 2023
Study Registration Dates
First Submitted
April 15, 2016
First Submitted That Met QC Criteria
December 5, 2016
First Posted (Estimated)
December 6, 2016
Study Record Updates
Last Update Posted (Estimated)
January 19, 2024
Last Update Submitted That Met QC Criteria
January 17, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Chronic Pain
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Lidocaine
Other Study ID Numbers
- 1000052256
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain, Chronic
-
Pain ConcernThe Thistle Foundation; Health and Social Care Alliance Scotland (the ALLIANCE) and other collaboratorsCompletedChronic Pain | Chronic Pain Syndrome | Chronic Pain, Widespread | Chronic Pain Due to Trauma | Chronic Pain Due to Malignancy (Finding) | Chronic Pain Due to Injury | Chronic Pain Post-Procedural | Chronic Pain HipUnited Kingdom
-
Consorci Sanitari de l'Alt Penedès i GarrafRecruitingChronic Post Operative Pain | Chronic Post-surgical Pain | Chronic Knee PainSpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
University of Alabama, TuscaloosaPatient-Centered Outcomes Research Institute; East Carolina University; Whatley...CompletedPain | Chronic Pain | Chronic Pain Syndrome | Widespread Chronic Pain | Chronic Pain Due to InjuryUnited States
-
University of UtahRecruitingChronic Pain | Chronic Pain Syndrome | Widespread Chronic PainUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Evolve Restorative CenterFlowonix Medical; Celéri Health, Inc.; Advanced Infusion SolutionsCompletedPain, Chronic | Pain, Intractable | Chronic Nonmalignant PainUnited States
-
Assiut UniversityNot yet recruiting
-
Vastra Gotaland RegionActive, not recruitingPain, Chronic | Widespread Chronic PainSweden
-
Istanbul UniversityCompletedLow Back Pain, Mechanical, Biofeedback, Pain, Chronic
Clinical Trials on Lidocaine Infusion
-
Aswan University HospitalUnknown
-
University of Vermont Medical CenterTerminatedPain, Postoperative | Opioid UseUnited States
-
Hospital de BaseCompleted
-
University of Alabama at BirminghamTerminatedGynecologic CancerUnited States
-
Aretaieion University HospitalRecruitingPain, Postoperative | Pain, Acute | Ketamine | Pain, Chronic | Magnesium | Pain, Neuropathic | Lidocaine | Central Nervous System Depressants | Analgesics | Neurotransmitter Agents | Analgesics, Non-narcoticGreece
-
Anqing Municipal HospitalCompletedDexmedetomidine | Nausea and Vomiting, Postoperative | LidocaineChina
-
University of Texas Southwestern Medical CenterTerminated
-
Nordsjaellands HospitalInnovation Fund DenmarkCompleted
-
Ain Shams UniversityNot yet recruitingOpioid Use | Spine FusionEgypt
-
Stanford UniversityTerminatedRib FracturesUnited States